Wee1

The regulation of cell size is critical to ensure functionality of a cell. Besides environmental factors such as nutrients, growth factors and functional load, cell size is also controlled by a cellular cell size checkpoint.{{fact|date=December 2024}}

Wee1 is a component of this checkpoint. It is a kinase determining the timepoint of entry into mitosis, thus influencing the size of the daughter cells. Loss of Wee1 function will produce smaller than normal daughter cell, because cell division occurs prematurely.{{fact|date=December 2024}}

Its name is derived from the Scottish dialect word wee, meaning small - its discoverer Paul Nurse was working at the University of Edinburgh in Scotland at the time of discovery.{{cite journal |author=Nurse P |title=Wee beasties |journal=Nature |volume=432 |issue=7017 |pages=557 |date=December 2004 |pmid=15577889 |doi=10.1038/432557a |bibcode=2004Natur.432..557N |doi-access=free }}{{cite journal |vauthors=Nurse P, Thuriaux P | title = Regulatory genes controlling mitosis in the fission yeast Schizosaccharomyces pombe | journal = Genetics | volume = 96 | issue = 3 | pages = 627–37 |date=November 1980 | doi = 10.1093/genetics/96.3.627 | pmid = 7262540 | pmc = 1214365 }}

The discovery of the Wee1 gene is accredited to Paul Nurse, who first identified it in fission yeast (Schizosaccharomyces pombe) in 1978. In his initial experiments, Nurse demonstrated Wee1 to be a negative regulator of mitosis, such that Wee1+ activity was critical in preventing premature mitosis in Cdc25+ (a mitotic inducer) yeast cells and increased Wee1+ expression could further delay cell cycle progression until cells grew to be larger in size.{{cite journal |last1=Russell |first1=Paul |last2=Nurse |first2=Paul |title=Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog |journal=Cell |date=May 1987 |volume=49 |issue=4 |pages=559–567 |doi=10.1016/0092-8674(87)90458-2 |pmid=3032459 }} Following this data, Nurse, together with Pierre Thuriaux, analyzed fifty two Wee mutants undergoing mitosis – those lacking in Wee1 were comparatively smaller; their analysis led them to a model (later demonstrated to be true) where Wee1 is a dosage-dependent inhibitor of Cdc2, whose activity is required for a cell’s entry into M phase.{{cite journal |last1=Murray |first1=Andrew |title=Paul Nurse and Pierre Thuriaux on wee Mutants and Cell Cycle Control |journal=Genetics |date=December 2016 |volume=204 |issue=4 |pages=1325–1326 |doi=10.1534/genetics.116.197186 |pmid=27927897 |pmc=5161264 }} As a result of these discoveries and its contributions to our understanding of cell cycle control, Nurse went on to win the 2001 Nobel Prize in Medicine or Physiology (shared also with Lee Hartwell and Tim Hunt).{{cite web | url=https://www.nobelprize.org/prizes/medicine/2001/nurse/facts/ | title=The Nobel Prize in Physiology or Medicine 2001 }}

Wee1 is part of a family of three serine/threonine protein kinases, consisting of Wee1 (also known as WEE1A), PKMYT1, and Wee2 (WEE1B).{{cite journal |last1=Ghelli Luserna di Rorà |first1=Andrea |last2=Cerchione |first2=Claudio |last3=Martinelli |first3=Giovanni |last4=Simonetti |first4=Giorgia |title=A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target |journal=Journal of Hematology & Oncology |date=December 2020 |volume=13 |issue=1 |page=126 |doi=10.1186/s13045-020-00959-2 |doi-access=free |pmid=32958072 |pmc=7507691 }} These three kinases have similar sequences in their respective kinase domains, but exhibit differences in their localization, regulation, and activation patterns. PKMYT1 is the only one of the three that is not typically found in the nucleus, but rather, is associated with the membranes of the endoplasmic reticulum and golgi apparatus.{{cite web | url=https://bellbrooklabs.com/pkmyt1-in-cell-cycle-regulation-and-cancer-therapeutics/#:~:text=While%20WEE1%20functions%20primarily%20in,between%20the%20nucleus%20and%20cytoplasm | title=PKMYT1 in Cell Cycle Regulation and Cancer Therapeutics | date=5 March 2024 }} And while Wee1 and PKMYT1 both play critical roles in regulating entry into mitosis (i.e. working together to inhibit Cdk1 as it moves in / out of the cell nucleus), WEE1B was first discovered in Xenopus oocytes and is most active at the metaphase II exit point of meiosis prior to fertilization.{{cite journal |last1=Esposito |first1=Francesca |last2=Giuffrida |first2=Raffaella |last3=Raciti |first3=Gabriele |last4=Puglisi |first4=Caterina |last5=Forte |first5=Stefano |title=Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy |journal=International Journal of Molecular Sciences |date=October 2021 |volume=22 |issue=19 |pages=10689 |doi=10.3390/ijms221910689 |doi-access=free |pmid=34639030 |pmc=8508993 }} Additionally, WEE1B is not as well-researched in the field of oncology as compared to its family members (both of which have better understood roles in cancer development), as there does not seem to be much evidence supporting WEE1B’s role in tumorigenesis.

File:Cellcycleprotein Wee1.svg

Wee1 inhibits Cdk1 by phosphorylating it on two different sites, Tyr15 and Thr14.{{cite journal |vauthors=Den Haese GJ, Walworth N, Carr AM, Gould KL |title=The Wee1 protein kinase regulates T14 phosphorylation of fission yeast Cdc2 |journal=Mol Biol Cell |volume=6 |issue=4 |pages=371–85 |year=1995 |pmid=7626804 |doi= 10.1091/mbc.6.4.371|pmc=301198}} Cdk1 is crucial for the cyclin-dependent passage of the various cell cycle checkpoints.

At least three checkpoints exist for which the inhibition of Cdk1 by Wee1 is important:

• G2/M checkpoint: Wee1 phosphorylates the amino acids Tyr15 and Thr14 of Cdk1, which keeps the kinase activity of Cdk1 low and prevents entry into mitosis; in S. pombe further cell growth can occur. Wee1 mediated inactivation of Cdk1 has been shown to be ultrasensitive as a result of substrate competition.{{cite journal |last1=Kim |first1=Sun Young |last2=Ferrell |first2=James E. |title=Substrate Competition as a Source of Ultrasensitivity in the Inactivation of Wee1 |journal=Cell |date=March 2007 |volume=128 |issue=6 |pages=1133–1145 |doi=10.1016/j.cell.2007.01.039 |pmid=17382882 |doi-access=free }} During mitotic entry the activity of Wee1 is decreased by several regulators and thus Cdk1 activity is increased. In S. pombe, Pom1, a protein kinase, localizes to the cell poles. This activates a pathway in which Cdr2 inhibits Wee1 through Cdr1. Cdk1 itself negatively regulates Wee1 by phosphorylation, which leads to a positive feedback loop. The decreased Wee1 activity alone is not sufficient for mitotic entry: Synthesis of cyclins and an activating phosphorylation by a Cdk activating kinase (CAK) are also required.{{cite journal |last1=Coleman |first1=Thomas R. |last2=Dunphy |first2=William G. |title=Cdc2 regulatory factors |journal=Current Opinion in Cell Biology |date=December 1994 |volume=6 |issue=6 |pages=877–882 |doi=10.1016/0955-0674(94)90060-4 |pmid=7880537 }}
• Cell size checkpoint: There is evidence for the existence of a cell size checkpoint, which prevents small cells from entering mitosis. Wee1 plays a role in this checkpoint by coordinating cell size and cell cycle progression.{{cite journal |author=Kellogg DR |title=Wee1-dependent mechanisms required for coordination of cell growth and cell division |journal=J Cell Sci |volume=116 |issue=24 |pages=4883–90 |year=2003 |pmid=14625382 |doi=10.1242/jcs.00908 }}
• DNA damage checkpoint: This checkpoint also controls the G2/M transition. In S. pombe this checkpoint delays the mitosis entry of cells with DNA damage (for example induced by gamma radiation). The lengthening of the G2 phase depends on Wee1; wee1 mutants have no prolonged G2 phase after gamma irradiation.{{cite journal |vauthors=Rowley R, Hudson J, Young PG |title=The wee1 protein kinase is required for radiation-induced mitotic delay |journal=Nature |volume=356 |issue=6367 |pages=353–5 |year=1992 |pmid=1549179 |doi=10.1038/356353a0 |bibcode=1992Natur.356..353R }}

Epigenetic function of Wee1 kinase has also been reported. Wee1 was shown to phosphorylate histone H2B at tyrosine 37 residue which regulated global expression of histones.{{cite journal |vauthors=Mahajan K, Fang B, Koomen JM, Mahajan NP |title=H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes. |journal= Nature Structural & Molecular Biology |volume=19 |issue=9 |pages=930–7 |year=2012 |pmid= 22885324 |doi= 10.1038/nsmb.2356|pmc=4533924}}

{{cite journal |vauthors=Mahajan K, Mahajan NP |title=WEE1 tyrosine kinase, a novel epigenetic modifier. |journal= Trends Genet.|volume= 29|issue= 7|pages= 394–402|year=2013 |pmid= 23537585 |doi= 10.1016/j.tig.2013.02.003|pmc=3700603}}

{{infobox protein

|Name=human WEE1 homolog (S. pombe)

|image=

|width=

|HGNCid=12761

|Symbol=WEE1

|AltSymbols=

|EntrezGene=7465

|OMIM=193525

|RefSeq=NM_003390

|UniProt=P30291

|PDB=

|ECnumber=

|Chromosome=11

|Arm=p

|Band=15.3-15.1

|LocusSupplementaryData=

}}

{{infobox protein

|Name=human WEE1 homolog 2 (S. pombe)

|image=

|width=

|HGNCid=19684

|Symbol=WEE2

|AltSymbols=

|EntrezGene=494551

|OMIM=

|RefSeq= NM_001105558

|UniProt= P0C1S8

|PDB=

|ECnumber=

|Chromosome=7

|Arm=q

|Band=32

|LocusSupplementaryData=-q32

}}

The WEE1 gene has two known homologues in humans, WEE1 (also known as WEE1A) and WEE2 (WEE1B). The corresponding proteins are Wee1-like protein kinase and Wee1-like protein kinase 2 which act on the human Cdk1 homologue Cdk1.

The homologue to Wee1 in budding yeast Saccharomyces cerevisiae is called Swe1.

In S. pombe, Wee1 is phosphorylated

Cdk1 and cyclin B make up the maturation promoting factor (MPF) which promotes the entry into mitosis. It is inactivated by phosphorylation through Wee1 and activated by the phosphatase Cdc25C. Cdc25C in turn is activated by Polo kinase and inactivated by Chk1. Thus in S. pombe Wee1 regulation is mainly under the control of phosphorylation through the polarity kinase, Pom1's, pathway including Cdr2 and Cdr1.{{cite journal |vauthors=Boddy MN, Furnari B, Mondesert O, Russell P |title=Replication checkpoint enforced by kinases Cds1 and Chk1 |journal=Science |volume=280 |issue=5365 |pages=909–12 |date=May 1998 |pmid=9572736 |doi= 10.1126/science.280.5365.909|bibcode=1998Sci...280..909B }}{{cite journal |vauthors=Wu L, Russell P |title=Nim1 kinase promotes mitosis by inactivating Wee1 tyrosine kinase |journal=Nature |volume=363 |issue=6431 |pages=738–41 |date=June 1993 |pmid=8515818 |doi=10.1038/363738a0 |bibcode=1993Natur.363..738W }}{{cite journal |vauthors=Coleman TR, Tang Z, Dunphy WG |title=Negative regulation of the wee1 protein kinase by direct action of the nim1/cdr1 mitotic inducer |journal=Cell |volume=72 |issue=6 |pages=919–29 |date=March 1993 |pmid=7681363 |doi= 10.1016/0092-8674(93)90580-J }}{{cite journal |vauthors=Tang Z, Coleman TR, Dunphy WG |title=Two distinct mechanisms for negative regulation of the Wee1 protein kinase |journal=EMBO J. |volume=12 |issue=9 |pages=3427–36 |date=September 1993 |pmid=7504624 |pmc=413619 |doi= 10.1002/j.1460-2075.1993.tb06017.x}}

At the G2/M transition, Cdk1 is activated by Cdc25 through dephosphorylation of Tyr15. At the same time, Wee1 is inactivated through phosphorylation at its C-terminal catalytic domain by Nim1/Cdr1. Also, the active MPF will promote its own activity by activating Cdc25 and inactivating Wee1, creating a positive feedback loop, though this is not yet understood in detail.

Higher eukaryotes regulate Wee1 via phosphorylation and degradation

In higher eukaryotes, Wee1 inactivation occurs both by phosphorylation and degradation.{{cite journal |vauthors=Watanabe N, Broome M, Hunter T |title=Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle |journal=EMBO J. |volume=14 |issue=9 |pages=1878–91 |date=May 1995 |pmid=7743995 |pmc=398287 |doi= 10.1002/j.1460-2075.1995.tb07180.x}}

The protein complexβ-transducin repeat-containing protein 1/2 (β-TrCP1/2) F-box protein-containing SKP1/Cul1/F-box protein complex SCF^β-TrCP1/2 is an E3 ubiquitin ligase that functions in Wee1A ubiquitination. The M-phase kinases Polo-like kinase (Plk1) and Cdc2 phosphorylate two serine residues in Wee1A which are recognized by SCF^β-TrCP1/2.{{cite journal |author=Watanabe N |title=M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=101 |issue=13 |pages=4419–24 |date=March 2004 |pmid=15070733 |pmc=384762 |doi=10.1073/pnas.0307700101 |author2=Arai H |author3=Nishihara Y |display-authors=3 |last4=Taniguchi |first4=M |last5=Watanabe |first5=N |last6=Hunter |first6=T |last7=Osada |first7=H|bibcode=2004PNAS..101.4419W |doi-access=free }}

S. cerevisiae homologue Swe1

In S. cerevisiae, cyclin-dependent kinase Cdc28 (Cdk1 homologue) is phosphorylated by Swe1 (Wee1 homologue) and dephosphorylated by Mih1 (Cdc25 homologue). Nim1/Cdr1 homologue in S. cerevisiae, Hsl1, together with its related kinases Gin4 and Kcc4 localize Swe1 to the bud-neck. Bud-neck associating kinases Cla4 and Cdc5 (polo kinase homologue) phosphorylate Swe1 at different stages of the cell cycle. Swe1 is also phosphorylated by Clb2-Cdc28 which serves as a recognition for further phosphorylation by Cdc5.

The S. cerevisiae protein Swe1 is also regulated by degradation. Swe1 is hyperphosphorylated by Clb2-Cdc28 and Cdc5 which may be a signal for ubiquitination and degradation by SCF E3 ubiquitin ligase complex as in higher eukaryotes.{{cite journal |last1=Lee |first1=Kyung S. |last2=Asano |first2=Satoshi |last3=Park |first3=Jung-Eun |last4=Sakchaisri |first4=Krisada |last5=Erikson |first5=Raymond L. |title=Monitoring the Cell Cycle by Multi-Kinase-Dependent Regulation of Swe1/Wee1 in Budding Yeast |journal=Cell Cycle |date=23 October 2005 |volume=4 |issue=10 |pages=1346–1349 |doi=10.4161/cc.4.10.2049 |pmid=16123596 |doi-access=free }}

The mitosis promoting factor MPF also regulates DNA-damage induced apoptosis. Negative regulation of MPF by WEE1 causes aberrant mitosis and thus resistance to DNA-damage induced apoptosis. Kruppel-like factor 2 (KLF2) negatively regulates human WEE1, thus increasing sensitivity to DNA-damage induced apoptosis in cancer cells.{{cite journal |author=Wang F |title=Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis |journal=Oncogene |volume=24 |issue=24 |pages=3875–85 |date=June 2005 |pmid=15735666 |doi=10.1038/sj.onc.1208546 |author2=Zhu Y |author3=Huang Y |display-authors=3 |last4=McAvoy |first4=Sarah |last5=Johnson |first5=William B |last6=Cheung |first6=Tak Hong |last7=Chung |first7=Tony Kwok Hung |last8=Lo |first8=Keith Wing Kit |last9=Yim |first9=So Fan|doi-access=free }}

While multiple studies have examined the relationship between Wee1 expression and tumors, there is not a strong consensus on whether Wee1 acts as an oncogene or a tumor suppressor in cancer tissues. In some cases, studies have reported an observed overexpression of Wee1 in solid tumors / cancers like glioblastoma, hepatocellular carcinoma, melanoma, and more, as well as an association between elevated Wee1 expression and negative prognostic factors such as chemotherapy / radiotherapy resistance or other proliferation biomarkers; there are also accounts on an increased prevalence of upregulated Wee1 in instances there is also p53 loss of function. However, there are other reports which show occurrences of Wee1 downregulation (or a complete lack thereof) in cancer tissues such as non-small cell lung cancer (NSCLC), colon cancer, etc. Moreover, in certain cancers like breast cancer, there are conflicting / controversial reports.{{cite journal |last1=Wang |first1=Zizhuo |last2=Li |first2=Wenting |last3=Li |first3=Fuxia |last4=Xiao |first4=Rourou |title=An update of predictive biomarkers related to WEE1 inhibition in cancer therapy |journal=Journal of Cancer Research and Clinical Oncology |date=January 2024 |volume=150 |issue=1 |page=13 |doi=10.1007/s00432-023-05527-y |pmid=38231277 |pmc=10794259 }}{{cite journal |last1=Do |first1=Khanh |last2=Doroshow |first2=James H. |last3=Kummar |first3=Shivaani |title=Wee1 kinase as a target for cancer therapy |journal=Cell Cycle |date=October 2013 |volume=12 |issue=19 |pages=3348–3353 |doi=10.4161/cc.26062 |pmid=24013427 |pmc=3865011 }} Taken together, this discussion may signal that the application and manipulation of Wee1 will likely be situation-dependent.

Wee1 is very rarely mutated in cancer patients, with mutations seen at an overall frequency of around 1.2%. There is little data on how mutations affect tumor progression.

Wee1 inhibition has been a growing therapeutic area of interest. Contrary to perhaps the typical rationale behind using inhibitor drugs to trigger cell cycle arrest, Wee1 inhibitors instead disrupt the S / G2 checkpoints to prematurely induce mitosis in cells; this mechanism thus promotes a phenomenon called “mitotic catastrophe” – increased DNA damage (insufficient repair or new events such as double-stranded breaks) that ultimately lead to apoptosis.{{cite journal |last1=Zhang |first1=Chi |last2=Peng |first2=Ke |last3=Liu |first3=Qing |last4=Huang |first4=Qihong |last5=Liu |first5=Tianshu |title=Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors |journal=Critical Reviews in Oncology/Hematology |date=January 2024 |volume=193 |pages=104233 |doi=10.1016/j.critrevonc.2023.104233 |pmid=38103761 }} At the cellular level, inhibiting Wee1 significantly reduces the presence of Tyr15, which consequently allows for Cdk1 kinase activity to build up and trigger entry into mitosis.

To date, there have not been many Wee1 inhibitors developed and at the clinical stage. Adavosertib (AZD1775, MK1755), developed by AstraZeneca, is a small molecule Wee1 inhibitor, and was the first of its kind to reach clinical trials.https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adavosertib{{full|date=December 2024}} Although in 2022, the company itself removed the drug from its pipeline, multiple trials testing adavosertib as both a monotherapy or in combination were conducted. Results from randomized phase II trial FOCUS4-C demonstrated an around 2 month progression-free survival (PFS) improvement in those treated with adavosertib alone (versus the active monitoring control group);{{cite journal |last1=Seligmann |first1=Jenny F. |last2=Fisher |first2=David J. |last3=Brown |first3=Louise C. |last4=Adams |first4=Richard A. |last5=Graham |first5=Janet |last6=Quirke |first6=Philip |last7=Richman |first7=Susan D. |last8=Butler |first8=Rachel |last9=Domingo |first9=Enric |last10=Blake |first10=Andrew |last11=Yates |first11=Emma |last12=Braun |first12=Michael |last13=Collinson |first13=Fiona |last14=Jones |first14=Rob |last15=Brown |first15=Ewan |last16=de Winton |first16=Emma |last17=Humphrey |first17=Timothy C. |last18=Parmar |first18=Mahesh |last19=Kaplan |first19=Richard |last20=Wilson |first20=Richard H. |last21=Seymour |first21=Matthew |last22=Maughan |first22=Timothy S. |title=Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring |journal=Journal of Clinical Oncology |date=20 November 2021 |volume=39 |issue=33 |pages=3705–3715 |doi=10.1200/JCO.21.01435 |pmid=34538072 |pmc=8601321 }} meanwhile, another trial evaluating the efficacy of adavosertib in both patients with solid tumors and clear cell renal cell carcinoma observed no objective responses (with stable disease as the best response in 10/18 enrolled patients).{{cite journal |last1=Maldonado |first1=Edward |last2=Rathmell |first2=W. Kimryn |last3=Shapiro |first3=Geoffrey I. |last4=Takebe |first4=Naoko |last5=Rodon |first5=Jordi |last6=Mahalingam |first6=Devalingam |last7=Trikalinos |first7=Nikolaos A. |last8=Kalebasty |first8=Arash R. |last9=Parikh |first9=Mamta |last10=Boerner |first10=Scott A. |last11=Balido |first11=Celene |last12=Krings |first12=Gregor |last13=Burns |first13=Timothy F. |last14=Bergsland |first14=Emily K. |last15=Munster |first15=Pamela N. |last16=Ashworth |first16=Alan |last17=LoRusso |first17=Patricia |last18=Aggarwal |first18=Rahul R. |title=A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170) |journal=Cancer Research Communications |date=July 2024 |volume=4 |issue=7 |pages=1793–1801 |doi=10.1158/2767-9764.CRC-24-0213 |pmid=38920407 |pmc=11264598 |url=https://escholarship.org/content/qt1mf6v5z2/qt1mf6v5z2.pdf }} Other studies examining the effect of adavosertib in combination with other treatments (chemotherapy, radiotherapy, etc.) saw varying levels of impact, with the most promising data coming from trials for gynecological cancer patients. In one phase II trial using the Wee1 inhibitor in combination with carboplatin (a chemotherapy drug) in p53-mutated ovarian cancer patients, an overall response rate of 41% and median PFS of 5.6 months was observed;{{cite journal |last1=Embaby |first1=Alaa |last2=Kutzera |first2=Joachim |last3=Geenen |first3=Jill J. |last4=Pluim |first4=Dick |last5=Hofland |first5=Ingrid |last6=Sanders |first6=Joyce |last7=Lopez-Yurda |first7=Marta |last8=Beijnen |first8=Jos H. |last9=Huitema |first9=Alwin D.R. |last10=Witteveen |first10=Petronella O. |last11=Steeghs |first11=Neeltje |last12=van Haaften |first12=Gijs |last13=van Vugt |first13=Marcel A.T.M. |last14=de Ridder |first14=Jeroen |last15=Opdam |first15=Frans L. |title=WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study |journal=Gynecologic Oncology |date=July 2023 |volume=174 |pages=239–246 |doi=10.1016/j.ygyno.2023.05.063 |pmid=37236033 |url=https://pure.rug.nl/ws/files/672260328/1_s2.0_S0090825823003049_main.pdf }} another combining gemcitabine (also a chemotherapy drug) and adavosertib in recurrent ovarian cancer patients reported a significant improvement in PFS (4.6 months in the treatment group vs. 3.0 months in the placebo group).{{cite journal |last1=Lheureux |first1=Stephanie |last2=Cristea |first2=Mihaela C |last3=Bruce |first3=Jeffrey P |last4=Garg |first4=Swati |last5=Cabanero |first5=Michael |last6=Mantia-Smaldone |first6=Gina |last7=Olawaiye |first7=Alexander B |last8=Ellard |first8=Susan L |last9=Weberpals |first9=Johanne I |last10=Wahner Hendrickson |first10=Andrea E |last11=Fleming |first11=Gini F |last12=Welch |first12=Stephen |last13=Dhani |first13=Neesha C |last14=Stockley |first14=Tracy |last15=Rath |first15=Prisni |last16=Karakasis |first16=Katherine |last17=Jones |first17=Gemma N |last18=Jenkins |first18=Suzanne |last19=Rodriguez-Canales |first19=Jaime |last20=Tracy |first20=Michael |last21=Tan |first21=Qian |last22=Bowering |first22=Valerie |last23=Udagani |first23=Smitha |last24=Wang |first24=Lisa |last25=Kunos |first25=Charles A |last26=Chen |first26=Eric |last27=Pugh |first27=Trevor J |last28=Oza |first28=Amit M |title=Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial |journal=The Lancet |date=January 2021 |volume=397 |issue=10271 |pages=281–292 |doi=10.1016/S0140-6736(20)32554-X |pmid=33485453 |pmc=10792546 }} It seems that a major contributor to the halt / limited continued development of adavosertib is its toxicity; several of the aforementioned studies cited patients experiencing Grade 3+ adverse events including anemia, gastrointestinal toxicities, neutropenia, thrombocytopenia, and more.

Five other Wee1 inhibitors (ZN-c3, Debio-0123, SY-4835, ACR-2316, and IMP7086) are still actively under clinical evaluation. Phase I data for ZN-c3 (azenosertib, developed by Zentalis Therapeutics) shows early signs of clinical activity (2 partial responses and 5 stable disease out of 16 dosed patients) and tolerability;{{cite journal |last1=Tolcher |first1=Anthony |last2=Mamdani |first2=Hirva |last3=Chalasani |first3=Pavani |last4=Meric-Bernstam |first4=Funda |last5=Gazdoiu |first5=Mihaela |last6=Makris |first6=Lukas |last7=Pultar |first7=Philippe |last8=Voliotis |first8=Dimitris |title=Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors |journal=Cancer Research |date=July 2021 |volume=81 |issue=13_Supplement |pages=CT016 |doi=10.1158/1538-7445.AM2021-CT016 }} however, several azenosertib trials were temporarily placed on clinical hold by the FDA between June and September 2024 after two patient deaths occurred.https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-provides-update-azenosertib-clinical{{full|date=December 2024}}

Wee1 acts as a dosage-dependent inhibitor of mitosis.{{cite journal |vauthors=Russell P, Nurse P |title=Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog |journal=Cell |volume=49 |issue=4 |pages=559–67 |date=May 1987 |pmid=3032459 |doi= 10.1016/0092-8674(87)90458-2 }} Thus, the amount of Wee1 protein correlates with the size of the cells:

The fission yeast mutant wee1, also called wee1⁻, divides at a significantly smaller cell size than wildtype cells. Since Wee1 inhibits entry into mitosis, its absence will lead to division at a premature stage and sub-normal cell size. Conversely, when Wee1 expression is increased, mitosis is delayed and cells grow to a large size before dividing.

• Wee1-like protein kinase
• Cell cycle

{{Reflist|2}}

• [http://www.sdbonline.org/fly/newgene/weekin1.htm Drosophila wee - The Interactive Fly]

{{Cell cycle proteins}}

{{Serine/threonine-specific protein kinases}}

{{Enzymes}}

{{Portal bar|Biology|border=no}}

Category:Cell cycle

Category:Fungal proteins

Category:EC 2.7.11